Semaglutide News and Research

Latest Semaglutide News and Research

Weight loss drug may change how obese people perceive taste

Weight loss drug may change how obese people perceive taste

Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

GLP-1 drugs may reduce pancreatitis risk in obese and diabetic patients

GLP-1 drugs may reduce pancreatitis risk in obese and diabetic patients

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Taking semaglutide once weekly may lower the chances of kidney disease, says study

Taking semaglutide once weekly may lower the chances of kidney disease, says study

Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patients

Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patients

SELECT trial shows semaglutide reduces kidney decline in obese patients

SELECT trial shows semaglutide reduces kidney decline in obese patients

Sharp uptick in youth using wegovy and ozempic, study reports

Sharp uptick in youth using wegovy and ozempic, study reports

Closed Loop Medicine appoints Paul Johnson as Non-Executive Director

Closed Loop Medicine appoints Paul Johnson as Non-Executive Director

Key studies on GLP-1 drugs, alpha-gal syndrome, and liver disease medications to be presented at DDW 2024

Key studies on GLP-1 drugs, alpha-gal syndrome, and liver disease medications to be presented at DDW 2024

High price of popular diabetes drugs deprives low-income people of effective treatment

High price of popular diabetes drugs deprives low-income people of effective treatment

From research to practice: Closing the divide in obesity management

From research to practice: Closing the divide in obesity management

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

New therapy shows greater weight loss in mice by targeting brain's appetite center

New therapy shows greater weight loss in mice by targeting brain's appetite center

Anti-obesity medications slash heart disease risk in obese patients, study finds

Anti-obesity medications slash heart disease risk in obese patients, study finds

Technology alone insufficient for meaningful weight loss in obesity, study shows

Technology alone insufficient for meaningful weight loss in obesity, study shows

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.